Terns appoints new Chief Legal Officer; CFO and General Counsel to depart in planned transitions

Terns Pharmaceuticals, Inc.

Elona Kogan appointed Chief Legal Officer effective July 29; previously CLO at Seer, Inc.
CFO Mark Vignola to leave by Feb 1, 2025 or upon successor; receives $475k severance plus $500k retention bonus.
General Counsel Bryan Yoon steps down, becomes COO/Special Counsel until Sep 3, 2024; receives $490,700 severance.
Search for new CFO underway; Vignola and Yoon remain in transition roles.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Mark Vignola

Chief Financial Officer

TERN · Terns Pharmaceuticals, Inc.

Effective: 2025-02-01
Filed: July 29, 2024, 7:59 PM ET

Dr. Vignola’s continued service as Chief Financial Officer for a transition period until the date of his separation from employment (the “Vignola Separation Date”), anticipated to be February 1, 2025.

Role change

Bryan Yoon

General Counsel

TERN · Terns Pharmaceuticals, Inc.

Effective: 2024-07-23
Filed: July 29, 2024, 7:59 PM ET

Effective upon the execution of the Yoon Separation Agreement, Mr. Yoon has assumed the title of Chief Operating Officer and Special Counsel and has ceased to serve as General Counsel and Secretary of the Company.

Departed

Bryan Yoon

Chief Operating Officer

TERN · Terns Pharmaceuticals, Inc.

Effective: 2024-09-03
Filed: July 29, 2024, 7:59 PM ET

The Yoon Separation Agreement provides for Mr. Yoon’s continued service as Chief Operating Officer and Special Counsel for a transition period until September 3, 2024 (the “Yoon Separation Date”). Mr. Yoon’s employment will terminate and he will cease to hold any positions with the Company as of the Yoon Separation Date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark Vignola departed as Chief Financial Officer at Terns Pharmaceuticals, Inc..

Action: resignation
Role: Chief Financial Officer

Exact text from the filing

Dr. Vignola’s continued service as Chief Financial Officer for a transition period until the date of his separation from employment (the “Vignola Separation Date”), anticipated to be February 1, 2025.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Bryan Yoon changed role as General Counsel at Terns Pharmaceuticals, Inc..

Action: role change
Role: General Counsel

Exact text from the filing

Effective upon the execution of the Yoon Separation Agreement, Mr. Yoon has assumed the title of Chief Operating Officer and Special Counsel and has ceased to serve as General Counsel and Secretary of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Bryan Yoon departed as Chief Operating Officer at Terns Pharmaceuticals, Inc..

Action: termination
Role: Chief Operating Officer

Exact text from the filing

The Yoon Separation Agreement provides for Mr. Yoon’s continued service as Chief Operating Officer and Special Counsel for a transition period until September 3, 2024 (the “Yoon Separation Date”). Mr. Yoon’s employment will terminate and he will cease to hold any positions with the Company as of the Yoon Separation Date.

View on SEC.gov

Terns Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-087284

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.